Almac Group, the global contract development and manufacturing organisation is delighted to have won the coveted Research and Development achievement award at this years’ Pharma Industry Awards.
The annual event aims to recognise and celebrate the most original and innovative individuals and companies that demonstrate excellence within the Irish Pharma sector and the glittering awards ceremony took place in the Ballsbridge Hotel, Dublin on the evening of Thursday 13th October.
Almac received the award for demonstrating its excellence in enzyme technology development through their "selectAZyme™" research program. This is achieved through the unique collaboration between the biocatalysis team within Almac's Sciences business unit and Arran Chemical Company which was acquired by the Almac Group in November 2015. The "selectAZyme™" program is centred around Almac's enzyme platform which delivers a diverse A-Z range of enzymes for development and scale-up within medicinal chemistry, metabolite synthesis and specialty chemicals for large scale manufacturing projects.
An independent panel of recognised and expert individuals within the pharmaceutical sector judged the entries and determined the winners based on a number of key attributes. Almac beat off stiff competition and clearly demonstrated its team integration, innovation, increased business performance, skills benefit to the Northern Irish and Irish economies plus the environmental benefits associated with biocatalysis technology to pick up the prestigious trophy.
Professor Tom Moody, Head of Biocatalysis and Isotope Chemistry at Almac & Head of Technology at Arran Chemical Company commented:
This award further demonstrates the combined capability, expertise and experience of the Almac and Arran Chemical Company teams. We are delighted to be recognised at the Pharma Industry Awards and pride ourselves on our ability to provide high quality, flexible and innovative solutions to meet our global clients' requirements.
About Almac Group
'Partnering to Advance Human Health'
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).